Résultats de la recherche
10
Tout
Rechercher les filtres
Mot-clé
immunotherapy
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
28 mars 2025 09h00 HE
|
Calidi Biotherapeutics, Inc
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
Immatics Announces Full Year 2024 Financial Results and Business Update
27 mars 2025 07h00 HE
|
https://immatics.com/
Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
27 mars 2025 06h00 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma
26 mars 2025 08h00 HE
|
Calidi Biotherapeutics, Inc
SAN DIEGO and LOS ANGELES, March 26, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of...
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
25 mars 2025 16h30 HE
|
Abpro Corporation
WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and...
Nouscom to Present Final Results from Successful Phase Ib/II Trial of NOUS-209 in People Living with Lynch Syndrome, Demonstrating Powerful Potential to Intercept Cancer in its Earliest Stages of Development
25 mars 2025 16h30 HE
|
Nouscom Srl
Lynch Syndrome (LS) is a common hereditary condition that significantly increases the risk of developing cancer, especially colorectal and endometrial cancersNOUS-209 is an off-the-shelf...
Next-Gen Immunotherapy: Trispecific Antibodies Show 260x Potency Over Traditional Treatments
20 mars 2025 10h24 HE
|
Research and Markets
Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Trispecific Antibodies Clinical Trials, Fast Track Status, Technology Platforms & Market Opportunity Outlook 2025" report has been added to ...
Interleukin-2 Market Size, Target Population, Competitive Landscape & Market Forecast to 2034: Japan Leads Interleukin-2 Market Growth, With NSCLC & Atopic Dermatitis Driving Demand
20 mars 2025 08h14 HE
|
Research and Markets
Dublin, March 20, 2025 (GLOBE NEWSWIRE) -- The "Interleukin-2 - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's...
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
13 mars 2025 16h15 HE
|
Candel Therapeutics
Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancerRecently announced positive final...
Allogeneic CAR-T Cell Patent Landscape and Forecast Report 2024-2032, Profiles of Artiva Biotherapeutics, Poseida Therapeutics, Nanjing Beiheng Biological Technology, NantCell, GC Cell, BMS, Compugen
13 mars 2025 11h02 HE
|
Research and Markets
Dublin, March 13, 2025 (GLOBE NEWSWIRE) -- The "Allogeneic CAR-T Cell Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global allogenic...